Results 31 to 40 of about 253,192 (255)

Efficacy and safety of levilimab in the treatment of rheumatoid arthritis in real-life clinical practice: first results of the HELIOS observational study

Современная ревматология
The efficacy and safety of levilimab (LVL) in patients with active rheumatoid arthritis (RA) has been confirmed in controlled clinical trials. This article presents the results of a preliminary analysis of a non-interventional observational study of LVL ...
A. M. Lila, I. Z. Gaydukova, O. N. Anoshenkova, I. G. Bannikova, I. B. Vinogradova, M. L. Goldman, S. Yu. Davidian, L. P. Evstigneeva, O. E. Epifanova, E. V. Zemerova, A. I. Zagrebneva, L. V. Ivanova, A. K. Karibova, I. V. Menshikova, O. N. Mironenko, M. P. Mikhailova, N. E. Nikulenkova, I. M. Patrikeeva, T. V. Plaksina, G. R. Savvina, R. R. Samigullina, L. E. Sarantseva, J. V. Usacheva, O. P. Ukhanova, G. F. Fatkhullina, A. L. Chudinov, I. A. Shafieva, S. P. Yakupova   +27 more
doaj   +1 more source

Acute lung injury timely associated with the administration of tocilizumab

Reumatismo
Dear editor, The interleukin-6 receptor inhibitor tocilizumab has been successfully used to treat various autoimmune diseases and has an acceptable, well-established safety profile...
Alojzija Hočevar, Anja Srpčič, Katja Lakota, Miša Fister   +3 more
doaj   +1 more source

Microarray Analysis of Gene Expression in Chondrosarcoma Cells Stimulated with Bee Venom

Journal of Pharmacopuncture, 2004
봉독은 관절염 치료를 비롯한 여러 질환에 그 응용범위가 넓어지고 있으며 기전규명과 새로운 치료효과 개발을 위한 연구가 필요하다. 연골의 파괴는 진행된 각종 관절병증의 공통 병리기전이며 연골세포의 기능이상은 이 기전에 중요한 의미를 지닌다. 사람 연골세포의 특성을 유지하고 있는 HTB-94 연골육종세포를 배양하고 봉독을 처치했을 때의 유전자 발현양상을 microarray를 이용하여 관찰하였다. 대조군에 비해 4배 이상 발현의 차이가 있는 경우를 유의한
Yin, Changshik, Koh, Hyung-gyun
doaj   +1 more source

A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling

iScience, 2021
Summary: Blocking the activity of cytokines is an efficient strategy to combat inflammatory diseases. Interleukin-6 (IL-6) fulfills its pro-inflammatory properties via its soluble receptor (IL-6 trans-signaling).
Juliane Lokau, Yvonne Garbers, Joachim Grötzinger, Christoph Garbers   +3 more
doaj   +1 more source

657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma

Journal for ImmunoTherapy of Cancer, 2020
Background Management of certain immune mediated adverse events (irAEs) can be challenging and may require prolonged/chronic immune suppression with corticosteroids or other immunosuppressant which could compromise and even reverse the efficacy of immune checkpoint inhibitors (ICI).
Adi Diab, Faisal Fa’ak, Noha Abdel-Wahab, Jean Tayar, Huifang Lu, Maria Suarez-Almazor, Stephen Gruschkus, Daniel Johnson, Chantal Saberian, May Daher, Sang Kim, Maryam Buni, Kaysia Ludford   +12 more
doaj   +2 more sources

Interleukin-6: A Potential Biomarker of Resistance to Multitargeted Receptor Tyrosine Kinase Inhibitors in Castration-resistant Prostate Cancer [PDF]

Urology, 2011
To determine if cellular interleukin-6 production predicts response to tyrosine kinase inhibitors (TKIs). As clinical experience using TKIs in patients with castration-resistant prostate cancer (CRPC) matures, Phase II trials show a heterogeneous response to sunitinib in CRPC patients.
Alexander, Kutikov, Peter, Makhov, Konstantin, Golovine, Daniel J, Canter, Mohit, Sirohi, Ryan, Street, Jay, Simhan, Robert G, Uzzo, Vladimir M, Kolenko   +8 more
openaire   +2 more sources

Structures of the interleukin 11 signalling complex reveal gp130 dynamics and the inhibitory mechanism of a cytokine variant

Nature Communications, 2023
Interleukin (IL-)11, an IL-6 family cytokine, has pivotal roles in autoimmune diseases, fibrotic complications, and solid cancers. Despite intense therapeutic targeting efforts, structural understanding of IL-11 signalling and mechanistic insights into ...
Riley D. Metcalfe, Eric Hanssen, Ka Yee Fung, Kaheina Aizel, Clara C. Kosasih, Courtney O. Zlatic, Larissa Doughty, Craig J. Morton, Andrew P. Leis, Michael W. Parker, Paul R. Gooley, Tracy L. Putoczki, Michael D. W. Griffin   +12 more
doaj   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

Inhibition of GSK3β and RIP1K Attenuates Glial Scar Formation Induced by Ischemic Stroke via Reduction of Inflammatory Cytokine Production

Frontiers in Pharmacology, 2020
In the chronic phase following ischemic stroke, glial scars can prevent axonal regeneration and the intensification of inflammation. The protective effect of inhibition of glycogen synthase kinase-3β (GSK3β) or receptor-interacting protein 1 kinase ...
Jin Liu, Yong-Ming Zhu, Yi Guo, Liang Lin, Zhan-Xiang Wang, Feng Gu, Xin-Yi Dong, Ming Zhou, Yi-Fan Wang, Hui-Ling Zhang   +9 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source